Account
Articles
21.06.2023
What are the current unmet needs in Oncology?

We explore the innovative assessment criteria for novel cancer therapies and the unmet needs in onco...

Read more
Articles
09.06.2023
What is a fair value for oncology combination pric...

We explore the issues faced by manufacturers and payers for oncology combination pricing and the pot...

Read more
Publications
19.10.2022
ISPOR 2022: Changing landscape of Orphan Drug Reim...

We compare the rates of positive reimbursement decisions in England and EU4 for orphan drugs approve...

Read more
Insider Insights
20.04.2022
Access to cancer drugs

According to the report, the financing of cancer drugs in Spain is “very high” with 90% of oncol...

Read more
Articles
28.03.2022
Correlating value with price in the US oncology ma...

An affordable and sustainable market access landscape is key to ensure patient access to life-saving...

Read more
Articles
16.03.2022
The impacts of Market Access combination pricing

We explore why combination pricing is an issue in the oncology space and why payers and manufacturer...

Read more
Insider Insights
03.03.2022
NICE recommends routine use of Zejula

The National Institute for Health and Care Excellence (NICE) has recommended GlaxoSmithKline’s Zej...

Read more
Insider Insights
15.02.2022
NICE recommends CDF use of dostarlimab

The CDF allows patients to access a new treatment while further data is collected on its clinical an...

Read more
Insider Insights
10.02.2022
Institute of Cancer Research labels NICE

In a statement the ICR said that it welcomes some of the changes, but that it wants to “see furthe...

Read more
Articles
30.11.2020
Pricing implications for cell and gene therapies

Cell and gene therapies - life saving opportunity for many patients

Read more

Stay in the know, subscribe to our newsletter

Be the first to receive exclusive content on the latest from the pharmaceutical and market access sector.